Cargando…

Ataxia-telangiectasia: future prospects

Ataxia-telangiectasia (A-T) is an autosomal recessive multi-system disorder caused by mutation in the ataxia-telangiectasia mutated gene (ATM). ATM is a large serine/threonine protein kinase, a member of the phosphoinositide 3-kinase-related protein kinase (PIKK) family whose best-studied function i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhary, Mohammed Wajid, Al-Baradie, Raidah Saleem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173637/
https://www.ncbi.nlm.nih.gov/pubmed/25258552
http://dx.doi.org/10.2147/TACG.S35759
_version_ 1782336240203333632
author Chaudhary, Mohammed Wajid
Al-Baradie, Raidah Saleem
author_facet Chaudhary, Mohammed Wajid
Al-Baradie, Raidah Saleem
author_sort Chaudhary, Mohammed Wajid
collection PubMed
description Ataxia-telangiectasia (A-T) is an autosomal recessive multi-system disorder caused by mutation in the ataxia-telangiectasia mutated gene (ATM). ATM is a large serine/threonine protein kinase, a member of the phosphoinositide 3-kinase-related protein kinase (PIKK) family whose best-studied function is as master controller of signal transduction for the DNA damage response (DDR) in the event of double strand breaks (DSBs). The DDR rapidly recognizes DNA lesions and initiates the appropriate cellular programs to maintain genome integrity. This includes the coordination of cell-cycle checkpoints, transcription, translation, DNA repair, metabolism, and cell fate decisions, such as apoptosis or senescence. DSBs can be generated by exposure to ionizing radiation (IR) or various chemical compounds, such as topoisomerase inhibitors, or can be part of programmed generation and repair of DSBs via cellular enzymes needed for the generation of the antibody repertoire as well as the maturation of germ cells. AT patients have immunodeficiency, and are sterile with gonadal dysgenesis as a result of defect in meiotic recombination. In the cells of nervous system ATM has additional role in vesicle dynamics as well as in the maintenance of the epigenetic code of histone modifications. Moderate levels of ATM are associated with prolonged lifespan through resistance to oxidative stress. ATM inhibitors are being viewed as potential radiosensitizers as part of cancer radiotherapy. Though there is no cure for the disease at present, glucocorticoids have been shown to induce alternate splicing site in the gene for ATM partly restoring its activity, but their most effective timing in the disease natural history is not yet known. Gene therapy is promising but large size of the gene makes it technically difficult to be delivered across the blood–brain barrier at present. As of now, apart from glucocorticoids, use of histone deacetylase inhibitors/EZH2 to minimize effect of the absence of ATM, looks more promising.
format Online
Article
Text
id pubmed-4173637
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41736372014-09-25 Ataxia-telangiectasia: future prospects Chaudhary, Mohammed Wajid Al-Baradie, Raidah Saleem Appl Clin Genet Review Ataxia-telangiectasia (A-T) is an autosomal recessive multi-system disorder caused by mutation in the ataxia-telangiectasia mutated gene (ATM). ATM is a large serine/threonine protein kinase, a member of the phosphoinositide 3-kinase-related protein kinase (PIKK) family whose best-studied function is as master controller of signal transduction for the DNA damage response (DDR) in the event of double strand breaks (DSBs). The DDR rapidly recognizes DNA lesions and initiates the appropriate cellular programs to maintain genome integrity. This includes the coordination of cell-cycle checkpoints, transcription, translation, DNA repair, metabolism, and cell fate decisions, such as apoptosis or senescence. DSBs can be generated by exposure to ionizing radiation (IR) or various chemical compounds, such as topoisomerase inhibitors, or can be part of programmed generation and repair of DSBs via cellular enzymes needed for the generation of the antibody repertoire as well as the maturation of germ cells. AT patients have immunodeficiency, and are sterile with gonadal dysgenesis as a result of defect in meiotic recombination. In the cells of nervous system ATM has additional role in vesicle dynamics as well as in the maintenance of the epigenetic code of histone modifications. Moderate levels of ATM are associated with prolonged lifespan through resistance to oxidative stress. ATM inhibitors are being viewed as potential radiosensitizers as part of cancer radiotherapy. Though there is no cure for the disease at present, glucocorticoids have been shown to induce alternate splicing site in the gene for ATM partly restoring its activity, but their most effective timing in the disease natural history is not yet known. Gene therapy is promising but large size of the gene makes it technically difficult to be delivered across the blood–brain barrier at present. As of now, apart from glucocorticoids, use of histone deacetylase inhibitors/EZH2 to minimize effect of the absence of ATM, looks more promising. Dove Medical Press 2014-09-10 /pmc/articles/PMC4173637/ /pubmed/25258552 http://dx.doi.org/10.2147/TACG.S35759 Text en © 2014 Chaudhary and Al-Baradie. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited
spellingShingle Review
Chaudhary, Mohammed Wajid
Al-Baradie, Raidah Saleem
Ataxia-telangiectasia: future prospects
title Ataxia-telangiectasia: future prospects
title_full Ataxia-telangiectasia: future prospects
title_fullStr Ataxia-telangiectasia: future prospects
title_full_unstemmed Ataxia-telangiectasia: future prospects
title_short Ataxia-telangiectasia: future prospects
title_sort ataxia-telangiectasia: future prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173637/
https://www.ncbi.nlm.nih.gov/pubmed/25258552
http://dx.doi.org/10.2147/TACG.S35759
work_keys_str_mv AT chaudharymohammedwajid ataxiatelangiectasiafutureprospects
AT albaradieraidahsaleem ataxiatelangiectasiafutureprospects